Law360 (December 4, 2018, 8:32 PM EST) -- The U.S. Department of Justice’s bombshell move to let Gilead Sciences Inc. escape a multibillion-dollar False Claims Act suit is sparking speculation about the DOJ’s motivations and the implications for similar suits alleging regulatory violations.
The DOJ disclosed its decision to let Gilead off the hook in a filing last week at the U.S. Supreme Court, which sought the government’s take on a case launched by former Gilead staffers Jeffrey and Sherilyn Campie.
At issue was whether Gilead’s alleged falsification of drug test results, among other things, would have jeopardized Medicare and Medicaid reimbursement under the Supreme Court’s game-changing Escobar decision....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!